Todas as matérias desta categoria, das mais recentes às mais antigas.
Solaris Energy Infrastructure (NYSE:SEI) announced it executed an agreement to acquire Global Energy Services Alliance to scale up its full-cycle power generation solutions.
Ceva (NASDAQ:CEVA) announced a landmark licensing agreement with a major U.S. software and AI platform company to support a custom AI silicon program aimed at next-generation intelligent computing devices.
Ionis Pharmaceuticals (NASDAQ:IONS) announced it completed patient enrollment in the pivotal pediatric cohort of its global Phase 3 REVEAL clinical study evaluating its investigational RNA-targeted medicine, obudanersen.
Pharvaris (NASDAQ:PHVS) announced the FDA accepted its regulatory application for its 20 mg hereditary angioedema on-demand treatment capsule.
Maximus (NYSE:MMS) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.33 per share to reward equity investors.
Lindsay (NYSE:LNN) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.38 per share.
AtaiBeckley (NASDAQ:ATAI) announced it completed dosing the final patient in its Phase 2b Elumina clinical trial evaluating VLS-01 for treatment-resistant depression.
AEVEX (NYSE:AVEX) announced it secured a $17.5 million follow-on defense contract under its Global Solutions business segment to continue delivering critical intelligence services.
Natera (NASDAQ:NTRA) announced publication of new clinical data in JAMA Oncology evaluating its Signatera molecular residual disease (MRD) test in patients with resected colorectal liver metastases (CRLM).
High Tide (NASDAQ:HITI) said it has approved a Temporary Shareholder Rights Plan alongside an Amended and Restated Shareholder Rights Plan, both dated June 26, 2026.
More than $2 trillion is being poured into the global arms race as nations attempt to be the first to master drones, hypersonic weapons, AI and other emerging technologies that may dominate future battlefields. Bloomberg's Gerry Doyle reports.
Clarivate (NYSE:CLVT) said it has agreed to sell its Life Sciences & Healthcare (LS&H) segment to Altaris for a total consideration of $600 million.
